Pharmalot

Pharmalot Ed Silverman

STAT Plus: Express Scripts sues FTC over a ‘biased’ report about pharmacy benefit managers

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an AstraZeneca bladder cancer drug, Genentech anxiety, and more

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more

Pharmalot Ed Silverman

STAT Plus: FDA scolds AbbVie over ‘misleading’ TV ad for a migraine pill featuring Serena Williams

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Novo weight loss study, a GSK vaccine failure, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Roivant deal, limited access to medicines and more

Pharmalot Ed Silverman

STAT Plus: Pharma is still struggling to widen access to medicines — and reach patients — in low- and middle-income countries

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Maryland law governing 340B discounts, an obesity drug, and more

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about FDA inspections, Lilly insulin trial results, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about China detaining AstraZeneca staff, pharma layoffs, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more

Pharmalot Ed Silverman

STAT Plus: Greece’s antitrust regulator probes Novartis over practices tied to a pricey eye drug

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Medicare drug prices, a Sanofi MS pill, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Wegovy study results, an Alnylam heart drug, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Zepbound pricing caveats, PBM congressional testimony, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Zantac court cases, a Neurocrine schizophrenia pill, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Lilly cutting Zepbound’s price; Pfizer selling direct to consumers, and more

Pharmalot Adam Feuerstein

STAT Plus: Pharmalittle: UCB selling a Chinese business, Tome layoffs, and more

Pharmalot Ed Silverman

STAT Plus: U.S. agency slaps down a J&J plan to switch payments for 340B hospitals

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more

Pharmalot Adam Feuerstein

STAT Plus: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about obesity drugs and suicidal thoughts, a FDA official’s conflicts, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more

Pharmalot Ed Silverman

STAT Plus: Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants?